Iloperidone
Fanapt (iloperidone) is a small molecule pharmaceutical. Iloperidone was first approved as Fanapt on 2009-05-06. It is used to treat schizophrenia and schizophrenia spectrum and other psychotic disorders in the USA. It is known to target 5-hydroxytryptamine receptor 7, 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 6, and D(2) dopamine receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| mental disorders | D001523 |
Trade Name
FDA
EMA
Fanapt (generic drugs available since 2022-05-05)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Iloperidone
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| FANAPT | Vanda Pharmaceuticals | N-022192 RX | 2009-05-06 | 7 products, RLD |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| fanapt | New Drug Application | 2018-09-25 |
| iloperidone | ANDA | 2022-12-21 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| schizophrenia | EFO_0000692 | D012559 | F20 |
| schizophrenia spectrum and other psychotic disorders | — | D019967 | — |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
206 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myeloid leukemia acute | D015470 | C92.0 | 40 | 63 | 18 | 4 | 4 | 104 | |
| Myelodysplastic syndromes | D009190 | D46 | 11 | 17 | 6 | 1 | 1 | 29 | |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | C91.0 | 2 | 5 | 6 | 6 | 2 | 18 | |
| Promyelocytic leukemia acute | D015473 | C92.4 | 2 | 1 | 3 | 2 | — | 8 | |
| Philadelphia chromosome | D010677 | — | 1 | — | 1 | — | 2 | ||
| Non-hodgkin lymphoma | D008228 | C85.9 | — | — | 1 | 1 | — | 2 | |
| Large b-cell lymphoma diffuse | D016403 | C83.3 | — | — | — | 1 | — | 1 | |
| Burkitt lymphoma | D002051 | C83.7 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | C95 | 12 | 30 | 20 | — | — | 54 | |
| Monocytic leukemia acute | D007948 | 4 | 6 | 2 | — | 1 | 11 | ||
| Myelomonocytic leukemia acute | D015479 | C92.5 | 4 | 5 | 1 | — | 1 | 10 | |
| Erythroblastic leukemia acute | D004915 | EFO_1001257 | C94.0 | 4 | 5 | 1 | — | 1 | 10 |
| Megakaryoblastic leukemia acute | D007947 | C94.2 | 3 | 5 | 1 | — | 1 | 9 | |
| Myeloid leukemia | D007951 | C92 | 2 | 5 | 1 | — | 1 | 7 | |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 1 | 4 | 1 | — | 1 | 6 |
| Anemia | D000740 | EFO_0004272 | D64.9 | 1 | 3 | 2 | — | 1 | 5 |
| Lymphoma | D008223 | C85.9 | — | — | 4 | — | 1 | 5 | |
| Myelomonocytic leukemia chronic | D015477 | C93.1 | 2 | 1 | 1 | — | 1 | 4 |
Show 5 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | 1 | 4 | — | — | — | 5 | |
| Basophilic leukemia acute | D015471 | C94.8 | 1 | 3 | — | — | — | 3 | |
| Eosinophilic leukemia acute | D015472 | 1 | 3 | — | — | — | 3 | ||
| Biphenotypic leukemia acute | D015456 | C95.0 | 1 | 3 | — | — | — | 3 | |
| Graft vs host disease | D006086 | D89.81 | — | 2 | — | — | — | 2 | |
| Myeloid sarcoma | D023981 | C92.3 | — | 1 | — | — | — | 1 | |
| Multiple myeloma | D009101 | C90.0 | — | 1 | — | — | — | 1 | |
| Myeloproliferative disorders | D009196 | D47.1 | — | 1 | — | — | — | 1 | |
| B-cell lymphoma | D016393 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Fibrosis | D005355 | 1 | — | — | — | — | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ILOPERIDONE |
| INN | iloperidone |
| Description | Iloperidone is a member of the class of piperidines that is the 4-acetyl-2-methoxyphenyl ether of 3-(piperidin-1-yl)propan-1-ol which is substituted at position 4 of the piperidine ring by a 6-fluoro-1,2-benzoxazol-3-yl group. A member of the group of second generation antipsychotics (also known as an atypical antipsychotics), it is used for the treatment of schizophrenia. It has a role as a serotonergic antagonist, a dopaminergic antagonist and a second generation antipsychotic. It is a monoamine, an organofluorine compound, a tertiary amino compound, a methyl ketone, a member of 1,2-benzoxazoles, a member of piperidines, an aromatic ether and an aromatic ketone. |
| Classification | Small molecule |
| Drug class | antipsychotics (risperidone type) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | COc1cc(C(C)=O)ccc1OCCCN1CCC(c2noc3cc(F)ccc23)CC1 |
Identifiers
| PDB | — |
| CAS-ID | 133454-47-4 |
| RxCUI | 73178 |
| ChEMBL ID | CHEMBL14376 |
| ChEBI ID | 65173 |
| PubChem CID | 71360 |
| DrugBank | DB04946 |
| UNII ID | VPO7KJ050N (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
HTR7
HTR7
HTR1A
HTR1A
HTR6
HTR6
DRD2
DRD2
Variants
Clinical Variant
No data
Financial
Fanapt - Vanda Pharmaceuticals
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 867 documents
View more details
Safety
Black-box Warning
Black-box warning for: Fanapt, Iloperidone
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
5,366 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more